Affiliation:
1. From the Hospital Universitario Doce de Octubre de Madrid, Madrid; Hospital de la Santa Creu I Sant Pau, Sant Pau; Hospital Miguel Servet de Zaragoza; Hospital Clínico Universitario de Zaragoza, Zaragoza; Hospital Clínico Universitario de Valencia, Valencia; Hospital del Mar de Barcelona, Barcelona; Hospital San Juan de Alicante; Hospital General de Alicante, Alicante; Hospital Universitario Marqués de Valdecilla de Santander, Santander; Fundación Jiménez Díaz, Madrid; Hospital Virgen del Rocío de...
Abstract
Purpose To compare the antitumor activity and toxicity of the two induction chemotherapy treatments of paclitaxel, cisplatin, and fluorouracil (FU; PCF) versus standard cisplatin and FU (CF), both followed by chemoradiotherapy (CRT), in locally advanced head and neck cancer (HNC). Patients and Methods Eligibility criteria included biopsy-proven, previously untreated, stage III or IV locally advanced HNC. Patients received either CF (cisplatin 100 mg/m2 on day 1 plus FU 1,000 mg/m2 continuous infusion on days 1 through 5) or PCF (paclitaxel 175 mg/m2 on day 1, cisplatin 100 mg/m2 on day 2, and FU 500 mg/m2 continuous infusion on days 2 through 6); both regimens were administered for three cycles every 21 days. Patients with complete response (CR) or partial response of greater than 80% in primary tumor received additional CRT (cisplatin 100 mg/m2 on days 1, 22, and 43 plus 70 Gy). Results A total of 382 eligible patients were randomly assigned to CF (n = 193) or PCF (n = 189). The CR rate was 14% in the CF arm v 33% in the PCF arm (P < .001). Median time to treatment failure was 12 months in the CF arm compared with 20 months in the PCF arm (log-rank test, P = .006; Tarone-Ware, P = .003). PCF patients had a trend to longer overall survival (OS; 37 months in CF arm v 43 months in PCF arm; log-rank test, P = .06; Tarone-Ware, P = .03). This difference was more evident in patients with unresectable disease (OS: 26 months in CF arm v 36 months in PCF arm; log-rank test, P = .04; Tarone-Ware, P = .03). CF patients had a higher occurrence of grade 2 to 4 mucositis than PCF patients (53% v 16%, respectively; P < .001). Conclusion Induction chemotherapy with PCF was better tolerated and resulted in a higher CR rate than CF. However, new trials that compare induction chemotherapy plus CRT versus CRT alone are needed to better define the role of neoadjuvant treatment.
Publisher
American Society of Clinical Oncology (ASCO)
Reference20 articles.
1. Ferlay J, Bray F, Pisani P, et al: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0 . International Agency for Research on Cancer (IARC) Cancer Base No. 5, Lyon, France, IARC Press, 2001
2. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?
3. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data
4. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck
5. Smith RE, Thorton D, Allen J: A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative studies. Semin Oncol 22: 41,1995-46, (suppl 6)
Cited by
386 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献